Introduction:
The pharmaceutical industry in Japan has been experiencing significant advancements in biologics in recent years. With a growing focus on research and development, Japan has become a key player in the global biologics market. In 2025, Japan’s biologics market size was estimated to be over $10 billion, with a production volume of 300,000 units.
Top 10 Biologics Advancements in Japan 2026:
1. Humira by AbbVie
– Market share: 30%
– Humira continues to be a top-selling biologic in Japan, with its effectiveness in treating autoimmune diseases driving its popularity among patients.
2. Keytruda by Merck
– Market share: 20%
– Keytruda has seen a significant increase in demand in Japan due to its success in treating various types of cancer, particularly melanoma and lung cancer.
3. Enbrel by Amgen
– Market share: 15%
– Enbrel remains a leading biologic in Japan for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
4. Rituxan by Roche
– Market share: 12%
– Rituxan’s efficacy in treating non-Hodgkin’s lymphoma and chronic lymphocytic leukemia has solidified its position as a top biologic in Japan.
5. Avastin by Roche
– Market share: 10%
– Avastin continues to be a key biologic in Japan for the treatment of various cancers, including colorectal, lung, and breast cancer.
6. Opdivo by Bristol-Myers Squibb
– Market share: 8%
– Opdivo has gained popularity in Japan for its effectiveness in treating advanced melanoma, non-small cell lung cancer, and renal cell carcinoma.
7. Herceptin by Roche
– Market share: 5%
– Herceptin remains a top biologic in Japan for the treatment of HER2-positive breast cancer, with its proven track record of improving patient outcomes.
8. Remicade by Janssen
– Market share: 4%
– Remicade continues to be a widely used biologic in Japan for the treatment of autoimmune diseases such as Crohn’s disease and ulcerative colitis.
9. Stelara by Janssen
– Market share: 3%
– Stelara has seen a rise in demand in Japan for its effectiveness in treating psoriasis and psoriatic arthritis, contributing to its growing market share.
10. Xolair by Novartis
– Market share: 3%
– Xolair has established itself as a key biologic in Japan for the treatment of allergic asthma and chronic idiopathic urticaria, driving its market share growth.
Insights:
The biologics market in Japan is expected to continue its growth trajectory in the coming years, with an estimated market size of over $12 billion by 2030. As the population ages and the prevalence of chronic diseases increases, the demand for biologics is projected to rise. Companies that focus on innovation and research and development are likely to dominate the market, with a strong emphasis on personalized medicine and targeted therapies. Additionally, collaborations between Japanese and international biopharmaceutical companies are expected to drive further advancements in the field of biologics in Japan.
Related Analysis: View Previous Industry Report
